CBIO
Crescent Biopharma
CBIO
CBIO
75 hedge funds and large institutions have $180M invested in Crescent Biopharma in 2019 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 19 increasing their positions, 19 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
4% less funds holding
Funds holding: 78 → 75 (-3)
12% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 25
66% less capital invested
Capital invested by funds: $535M → $180M (-$356M)
Holders
75
Holding in Top 10
2
Calls
$94K
Puts
$33K
Top Buyers
| 1 | +$31.7M | |
| 2 | +$15.1M | |
| 3 | +$852K | |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$713K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$575K |
Top Sellers
| 1 | -$36.3M | |
| 2 | -$20.5M | |
| 3 | -$18M | |
| 4 |
Jennison Associates
New York
|
-$16.9M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$13.1M |